<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388413/bin/OR-44-03-0863-g01.jpg"/> </div> <div class="text-side"> <h1>Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.</h1> <p>Representative immunohistochemical staining of PI3Kp110α. (A) Negative PI3Kp110α staining is observed in normal epithelium. (B) Weak staining for PI3Kp110α in OSCC with a Bryne's score of 3. (C) OSCC with Bryne's score of 3, demonstrates strong PI3Kp110α cytoplasmic and nuclear expression (staining index of 12). Magnification ×100.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32705230/" target="_blank">32705230</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>